Clinical Trial Update: Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 clinical trial (the DIVE study) evaluated the effects of empagliflozin, an SGLT2 inhibitor, in healthy volunteers with induced hypotonic h…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyponatremia
• Syndrome of Inappropriate Antidiuretic Hormone Secretion

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Inappropriate ADH Syndrome | Phase 2, Phase 3 | Status: COMPLETED